首页> 外文期刊>International Journal of Pharmacological Research >Fluindione and cefixime induced cutaneous bleeding manifestations A case report and review of literature
【24h】

Fluindione and cefixime induced cutaneous bleeding manifestations A case report and review of literature

机译:Fluindione和头孢克肟引起的皮肤出血表现一例并文献复习

获取原文
获取外文期刊封面目录资料

摘要

Fluindione an oral vitamin K antagonist is associated with various hemorrhagic and immunoallergic effects. This drug is also prone to produce various drug interactions, which if not taken into consideration while prescribing, might lead to increased incidence of adverse drug reactions for the patients. We report a case of drug interaction between fluindione and cefixime leading to cutaneous bleeding manifestations and raised PT-INR. Our patient was a 59 year old lady, a known case of rheumatic heart disease and mitral valve replacement, on tablet fluindione 20 mg for past 11 years. She was prescribed tablet cefixime 200 mg two times a day for three days for treatment of upper respiratory tract infection, following which she developed cutaneous bleeding manifestations like ecchymosis and purpura in left upper and lower limbs. She also had a rise in PT-INR level to 4.2, predisposing the patient to life threatening bleeding manifestations. Hence, caution is warranted while prescribing antibiotics to patients on oral anticoagulant therapy. Antibiotics that do not cause drug interaction with the anticoagulants must be selected in these patients. Also, periodic monitoring of PT INR in patients on anticoagulants especially when a new drug is co-prescribed is essential to curb the hazards of potential adverse drug interaction.
机译:口服维生素K拮抗剂Fluindione与各种出血和免疫过敏作用有关。该药物还易于产生各种药物相互作用,如果在开药时未予以考虑,则可能导致患者药物不良反应的发生率增加。我们报告一例氟丁二酮和头孢克肟之间的药物相互作用,导致皮肤出血表现和PT-INR升高。我们的患者是一位59岁的女士,患有风湿性心脏病和二尖瓣置换术的已知病例,过去11年服用了fluindione 20 mg片剂。每天两次给她服用200毫克的头孢克肟片治疗三天的上呼吸道感染,此后她在左上肢和下肢出现皮肤出血表现,如瘀斑和紫癜。她的PT-INR水平也升高到4.2,使患者容易遭受威胁生命的出血表现。因此,在口服抗凝治疗的患者处方抗生素时应谨慎行事。在这些患者中,必须选择不会引起药物与抗凝剂相互作用的抗生素。同样,定期监测抗凝剂患者的PT INR,尤其是在共同开出新药时,对于抑制潜在的不良药物相互作用的危害至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号